The limited effectiveness of EGFR TKI treatment for EGFR wild-type NSCLC is established [9,10], thus necessitating the identification of additional signalling pathways that can be targeted for therapeutic intervention. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.